Veru (VERU) Expected to Announce Quarterly Earnings on Thursday

Veru (NASDAQ:VERU) will likely be posting its Q1 2026 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Wednesday, December 17th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veru Stock Performance

VERU stock opened at $2.53 on Thursday. The firm has a market cap of $40.61 million, a PE ratio of -1.15 and a beta of -1.42. The firm’s 50 day moving average price is $2.44 and its 200-day moving average price is $3.22. Veru has a one year low of $2.10 and a one year high of $7.40.

Institutional Trading of Veru

Several hedge funds have recently made changes to their positions in VERU. Bank of America Corp DE grew its holdings in shares of Veru by 5.5% in the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after purchasing an additional 9,637 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Veru in the 3rd quarter valued at approximately $38,000. Osaic Holdings Inc. increased its position in shares of Veru by 11.9% during the second quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock worth $152,000 after acquiring an additional 27,954 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Veru in the third quarter valued at $110,000. Finally, Raymond James Financial Inc. boosted its holdings in Veru by 48.3% in the second quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after purchasing an additional 67,178 shares during the period. Institutional investors and hedge funds own 47.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on VERU shares. Canaccord Genuity Group assumed coverage on Veru in a research note on Thursday, December 18th. They set a “buy” rating and a $25.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Veru in a research report on Wednesday, January 21st. Oppenheimer restated an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Finally, Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Veru currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.